| Previous Close | 0.75 |
| Open | 0.75 |
| Day High | 0.76 |
| Day Low | 0.73 |
| 52-Week High | 4.35 |
| 52-Week Low | 0.67 |
| Volume | 24,178 |
| Average Volume | 123,743 |
| Market Cap | 18.23M |
| PE | -0.21 |
| EPS | -3.57 |
| Moving Average 50 Days | 0.95 |
| Moving Average 200 Days | 1.45 |
| Change | 0.01 |
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy
GlobeNewswire Inc.
Mar 10, 2026 12:30 PM GMT
Transaction expected to generate up to $35 million in upfront and milestone paymentsCelularity retains exclusive manufacturing rights, creating continued biomaterials revenue and margin opportunityOrganizational realignment reduces operating expenses
Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses
GlobeNewswire Inc.
Feb 10, 2026 1:30 PM GMT
FLORHAM PARK, N.J., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced receipt of $12.2 Million in net cash proceeds from the sale of appr
Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations
GlobeNewswire Inc.
Dec 26, 2025 1:30 PM GMT
While Celularity’s Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn LCDs, Celularity CEO Dr. Robert J. Hariri welcomed the recent action taken under the leadership of CMS Administrator Dr. Mehmet OzFL